Across TCGA pan-cancer cohorts, LINC02050 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC02050’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC02050 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02050 is over-expressed in tumor.
LIHC and PRAD are the cancer types where LINC02050 tumor–normal differential expression is most reproducible.